Interferon-a2b reduces neo-microvascular density in the 'normal' urothelium adjacent to the tumor after transurethral resection of superficial bladder carcinoma

Onkologie

Volumn 26, Issue 2, 2003, Pages 147-152

  Giannopoulos, A ^a   Adamakis, I ^a   Evangelou, K ^b   Giannopoulou, M ^a   Zacharatos, P ^b   Tsantoulis, P ^b   Perunovic, B ^c   Athanasiou, A ^b   Retalis, G ^a   Constandinidis, C ^a   Gorgoulis, Vassilis G ^b,d  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c WALSGRAVE HOSPITAL   (United Kingdom)

^d NONE   (Greece)

Author keywords

Bladder cancer; IFN a2b; Local immunotherapy; Microvascular density

Indexed keywords

ALPHA2B INTERFERON; CD31 ANTIGEN; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOSCOPY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRUSKAL WALLIS TEST; MALE; MICROVASCULATURE; RECURRENCE RISK; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; UROTHELIUM; WILCOXON SIGNED RANKS TEST;

ADMINISTRATION, INTRAVESICAL; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTOSCOPY; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0037977117     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069835     Document Type: Article

References (48)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics. 1997;47:5-27.
2. Bane BL, Rao JY, Hemstreet GP: Pathology and staging of bladder cancer. Semin Oncol 1996;23:546-570.
3. Catalona WJ: Urothelial tumors of the urinary tract; in Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr (eds): Campbell's Urology, ed 6. Philadelphia, Saunders, 1992, pp 1094-1158.
4. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR: Superficial bladder cancer: Progression and recurrence. J Urol 1983;130:1083-1086.
5. Morgan JDT, Bowsher W, Griffiths DFR, Matthews PN: Retionalization of follow-up in patients with non-invasive bladder tumors: A prelimnary report. Br J Urol 1991;67:158-161.
6. Torti MF, Lum LB: Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy. Cancer 1987;59:613-616.
7. Williams RD: Intravesical Interferon alfa in the treatment of superficial bladder cancer. Semin Oncol 1988;15:10-13.
8. Scorticatti CH, de la Pena NC, Bellora OG, Mariotto RA, Casabe AR, Comolli R: Systemic IFN-a2b treatment of multiple bladder papiloma grade I or II patients. Pilot study. J Interferon Res 1982;2:339-343.
9. Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M, Hannigan J: Alpha-interferon in superficial bladder cancer. A northern California Oncology Group study. J Clin Oncol 1988;6:476-483.
10. Glashan RW: A randomised controlled study of intravesical alfa-2b-interferon in carcinoma in situ of the bladder. J Urol 1990;144:658-661.
11. Giannakopoulos S, Gekas A, Alivizatos G, Sofras F, Becopoulos T, Dimopoulos C: Efficacy of escalating doses of intravesical interferon a-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol 1998;82:829-834.
12. Herr HW, Laudone VP, Whitmore WF Jr: An overview of intravesical therapy for superficial bladder tumors. J Urol 1987;138:1363-1368.
13. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Aparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995;153:1444-1450.
14. Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-183.
15. O'Donnell MA, Krohn J, De Wolf WC: Salvage intravesical therapy with Interferon-a2b plus low dose Bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom BCG alone previously failed. J Urol 2001;166:1300-1305.
16. Malmstrom PU: A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 2002;89:681-686.
17. Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E: The Finnbladder Group. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: A prospective randomized multicenter study -FinnBladder III long-term results. J Urol 2002;168:981-985.
18. Folkman J: What is the evidence that tumors are angiogenesis dependent. J Natl Cancer Inst 1990;82:4-8.
19. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
20. Bussolino F, Mantovani A, Persico G: Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997;22:251-256.
21. Folkman J: Angiogenesis: Initiation and modulation; in Day SB (ed): Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. New York, Raven Press, 1984, pp 201-209.
22. Folkman J: The role of angiogenesis in tumor growths. Semin Cancer Biol 1992;3:65-71.
23. Baron S, Tyring SK, Fleischmann WR Jr, Coppenharer DH, Niesel DW, Klimpel GR, Stanter GJ, Hughes TK: The interferons. Mechanism of action and clinical applications. J Am Med Assoc 1991; 266:1375-1383.
24. Sinkovics JG: Kaposi's sarcoma: Its oncogenes and growth factors. Clin Rev Oncol Hematol 1991;11: 87-107.
25. Kirn DH, Kramer A: Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma. J Natl Cancer Inst 1996;88:764-765.
26. Ezekowitz RAB, Mulliken JB, Folkman J: Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-1463.
27. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ: Inhibition of basic fibroblast growth factor expression, angiogenesis and growth of human bladder carcinoma in mice by systemic interferon-a administration. Cancer Res 1998;58:808-814.
28. Slaton JW, Perrotte P, Inoue K, Dinney CPN, Fidler IJ: Interferon-a-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are depended on optimisation of biological dose and schedule. Clin Cancer Res 1999;5:2726-2734.
29. Zacharatos P, Kotsinas A, Tsantoulis P, Evangelou K, Kletsas D, Asimacopoulos PJ, Doussis-Anagnostopoulou I, Pezzella F, Gatter K, Papavassiliou AG, Kittas C, Gorgoulis VG: Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas. Mol Med 2001;7:590-597.
30. Tsoli E, Zacharatos P, Dasiou-Plakida D, Peros J, Evangelou K, Zavras AI, Yannoukakos D, Konstandopoulou I, Asimakopoulos PJ, Kittas C, Gorgoulis VG: Growth index is independent of microvessel density in non-small cell lung carcinomas. Hum Pathol 2002;33:812-818.
31. Migliari R, El Demiry M, Muscas G, Usai E: Intravesical installation of interferon a in the treatment of bladder cancer. Br J Urol 1992;70:169-173.
32. Singh RK, Gutman M, Llansa N, Fidler IJ: Interferon-β prevents the upregulation of interleukin-8 expression in human melanoma cells. J Interferon Cytokine Res 1996;16:577-584.
33. Dinney CPN, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Filder IJ: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res 1998;58:808-814.
34. Oliveira IC, Sciavolino PJ, Lee TH: Downregulation of interleukin 8 gene expression in human fibroblasts: Unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci U S A 1992;89:9049-9053.
35. Van Damme J, Opdenakker G: Interaction of interferons with skin reactive cytokines: From interleukin-1 to interleukin-8. J Invest Dermatol 1990;95:90-93.
36. Jones A, Fujiyama C: Angiogenesis in urological malignancy: Prognostic indicator and therapeutic target. BJU Int 1999;83:535-556.
37. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Landau tumor suppressor protein. Cancer Res 1996;56:2299-2301.
38. Chow NH, Liu HS, Chan SH, Cheng HL, Tzai TS: Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res 1999;19:4593-4597.
39. Fabra A, Nakajima M, Bycana CD, Fidler IJ: Modulation of the invasive phenotype of human colon carcinoma cells by organ-specific fibroblasts of nude mice. Differentiation 1992;52:101-110.
40. Kato N, Nawa A, Tamakochi K, Kikkawa F, Suganuma N, Okamoto T, Goto S, Tomoda Y, Hamaguchi M, Nakajima M: Suppression of gelatinase production with decreased invasiveness of chorio-carcinoma cells by human recombinant interferon-β. Am J Obstet Gynecol 1995;172:601-606.
41. Gohji K, Fidler IJ, Tsan R, Radinsky R, von Eschenbach AC, Tsuruo T, Nakajima M: Human recombinant interferons-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells. Int J Cancer 1994;58:380-384.
42. Brouty-Boye D, Zetter BR: Inhibition of cell motility by interferon. Science 1980;208:516-518.
43. Heyns AD, Eldor A, Vlodavsky I, Kaiser N, Fridman R, Panet A: The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events: Studies with vascular smooth muscle cells and endothelial cells. Exp Cell Res 1985;161:297-306.
44. Feldman D, Goldstein AL, Cox DC, Grimley PM: Cultured human endothelial cells treated with recombinant leukocyte A interferon. Lab Invest 1988;59:584-589.
45. Yoshida A, Anand-Apte B, Zetter BR: Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 1996;13:57-64.
46. Tobelem G: Tumour angiogenesis: Clinical and therapeutic implications. Nouv Rev Fr Hematol 1990;32:405-406.
47. Borden EC: Interferons-expanding therapeutic roles. N Engl J Med 1992;26:1491-1493.
48. Ozawa S, Shinohara H, Kanayama HO, Bruns CJ, Bucana CD, Ellis LM, Davis DW, Fidler IJ: Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 2001;3:154-164.